Select Page

2016

Yuan Yuan, M.D., Ph.D.

Biomarker Correlative Studies for a Trial of Immunotherapy in Combination with a Selective Androgen Receptor Modulator in Patients with Advanced Androgen Receptor Positive Triple Negative Breast Cancer

Grant Amount: $150,655

Biomarker Correlative Studies for a Trial of Immunotherapy in Combination with a Selective Androgen Receptor Modulator in Patients with Advanced Androgen Receptor Positive Triple Negative Breast Cancer.

Triple negative breast cancers (TNBC) (estrogen, progesterone and HER2 negative), are typically not responsive to targeted therapies, can be more aggressive, and are more likely to recur than other breast cancer subtypes.  To counter these challenges, TNBCs have been suggested to be promising targets for immunotherapy, as well as targeting the Androgen Receptor in Androgen Receptor Positive TNBC, after it was found that this tumor type is highly infiltrated by immune cells.  Extending the reach of a current phase 2 study for treating these patients with a combination of immunotherapy along with the androgen receptor modulator, this work will analyze immune cell characteristics and biomarkers before and after treatment in order to predict response.  Once these predictive biomarkers are identified, this will help assess patient’s response and potential efficacy of immunotherapy.